Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer

• Published in: Technology in cancer research & treatment Vol. 19; p. 1533033820928435
• Main Authors: Wang, Ling-Cheng, Wang, Ling-Sheng, Li, Ai-Xia, Shi, Zhen-Zong, Li, Ya-Qiong, Huang, Wei, Chen, Shi-Man, Han, Fei, Zhu, De-Qiang
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 2020; Sage Publications Ltd; SAGE Publishing
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor - metabolism; Breast cancer; Breast Neoplasms - classification; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Carcinoma, Ductal, Breast - drug therapy; Carcinoma, Ductal, Breast - secondary; Chemotherapy; Docetaxel - administration & dosage; Doxorubicin; Doxorubicin - administration & dosage; ErbB-2 protein; Estrogen receptors; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Neoadjuvant Therapy - mortality; Neoplasm Invasiveness; Original; Patients; Prognosis; Receptor, ErbB-2 - metabolism; Receptors, Estrogen - metabolism; Receptors, Progesterone - metabolism; Response rates; Statistical analysis; Survival; Survival Rate; breast cancer; cavity radiosurgery; radiosurgery; stereotactic body radiation therapy; 3d conformal radiotherapy
• ISSN: 1533-0346; 1533-0338
• DOI: 10.1177/1533033820928435

Aim: The aim of this study is to characterize the effect of chemotherapy drug doxorubicin with neoadjuvant drug docetaxel for different molecular subtypes. Methods: A total of 83 patients with late-stage breast cancer were chosen to undergo treatment and compared to these patients to the combinational treatment to identify the molecular characteristics that can predict the responses. Results: Total response rate is 81.9% (68/83 patients). Among them, 7 patients show pathological complete response of 8.4%, 12 patients show clinical complete response of 14.5%, 49 patients show partial response of 59%, and 15 patients show stable disease of 18.1%. The comparison among different subtypes of breast cancer, including luminal A, luminal B, basal-like, and ERBB2+ subtypes, did not show statistical significant differences to the treatment of combinational treatment for the complete response rate, including pathological complete response and clinical complete response. Comparing with luminal A and luminal B subtypes, the ERBB2+ and basal-like subtypes have better complete response and response rate rates. The disease-free survival rate and overall survival rate at 29 months after treatment did not show statistical significant differences among different subtypes of patients with breast cancer. Conclusion: The molecular subtypes of breast cancer can predict responses to the combinational treatment of doxorubicin with docetaxel, and ERBB2+ and basal-like subtypes have better response rate and complete response rate. There is correlation of estrogen receptor and KI-67 level changes with response rate as well, where KI-67 high patients are more sensitive to the treatment.